


Is the Biosimilars Pathway Working for Patients?

JUST LOOK AT THE NUMBERS

In the **10 YEARS**

Since Congress established the biosimilars pathway



26

Biosimilars approved



5 Diseases
With biosimilar treatment options



Oncology



Hematology

15
Biosimilars on the market



Gastroenterology



Rheumatology



Dermatology

1,000+

Biosimilars in the pipeline¹



\$160

Billion Projected Savings

Over 5 years to the health care system²



70%

Physicians Are Confident

In standards for biosimilar interchangeability³

